Imaging of cell proliferation: Status and prospects

Journal of Nuclear Medicine

Volumn 49, Issue SUPPL.6, 2008, Pages

  Bading, James R ^a   Shields, Anthony F ^b,c  

^a City of Hope ^*  (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c KARMANOS CANCER INSTITUTE   (United States)

Author keywords

PET; Proliferation; Thymidine

Indexed keywords

1 (2' DEOXY 2' FLUORO 1 BETA D ARABINOFURANOSYL)THYMINE; 3' FLUOROTHYMIDINE; BROXURIDINE; FLOXURIDINE; FLUORODEOXYGLUCOSE F 18; IDOXURIDINE; THYMIDINE; THYMIDINE C 11; THYMIDINE KINASE 1; THYMIDINE PHOSPHATE; THYMINE;

CANCER DIAGNOSIS; CANCER STAGING; CELL PROLIFERATION; CHEMICAL STRUCTURE; DNA SYNTHESIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; TUMOR CELL; TUMOR GROWTH;

ANIMALS; CELL PROLIFERATION; DIDEOXYNUCLEOSIDES; HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 46749137956     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.046391     Document Type: Review

References (136)

1. 18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging. 2007;34:1339-1347.
2. Rubini JR, Cronkite EP, Bond VP, Fliedner TM. The metabolism and fate of tritiated thymidine in man. J Clin Invest. 1960;39:909-918.
3. 11C)thymidine. Proc Natl Acad Sci USA. 1972;69:988-992.
4. Mankoff DA, Shields AF, Krohn KA. PET imaging of cellular proliferation. Radiol Clin North Am. 2005;43:153-167.
5. 11C]-thymidine. Biochim Biophys Acta. 2004;1705:91-102.
6. Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol. 2005;16:1723-1739.
7. van Diest PJ, van der Wall E, Baak JP. Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol. 2004;57:675-681.
8. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311-322.
9. 11C labeled thymidine for tumor visualization using positron emission tomography. Int J Appl Radiat Isot. 1984;35:705-708.
10. Van de Wiele C, Lahorte C, Oyen W, et al. Nuclear medicine imaging to predict response to radiotherapy: a review. Int J Radiat Oncol Biol Phys. 2003;55:5-15.
11. 18F]fluorodeoxyglucose uptake with glucose transporter-1 expression and proliferation rate in human glioma and non-small-cell lung cancer. Nucl Med Commun. 2004;25:11-17.
12. Watanabe K, Nomori H, Ohtsuka T, et al. [F-18]Fluorodeoxyglucose positron emission tomography can predict pathological tumor stage and proliferative activity determined by Ki-67 in clinical stage IA lung adenocarcinomas. Jpn J Clin Oncol. 2006;36:403-409.
13. 18F-FDG. J Nucl Med. 2003;44:1426-1431.
14. Haberkorn U, Bellemann ME, Altmann A, et al. PET 2-fluoro-2-deoxyglucose uptake in rat prostate adenocarcinoma during chemotherapy with gemcitabine. J Nucl Med. 1997;38:1215-1221.
15. Schiepers C, Haustermans K, Geboes K, Filez L, Bormans G, Penninckx F. The effect of preoperative radiation therapy on glucose utilization and cell kinetics in patients with primary rectal carcinoma. Cancer. 1999;85:803-811.
16. van Waarde A, Been LB, Ishiwata K, Dierckx RA, Elsinga PH. Early response of sigma-receptor ligands and metabolic PET tracers to 3 forms of chemotherapy: an in vitro study in glioma cells. J Nucl Med. 2006;47:1538-1545.
17. Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med. 1993;34:414-419.
18. Higashi T, Tamaki N, Torizuka T, et al. FDG uptake, GLUT-1 glucose transporter, and cellularity in human pancreatic tumors. J Nucl Med. 1998;39:1727-1735.
19. 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2002;29:176-182.
20. Miyazawa H, Arai T, Iio M, Hara T. PET imaging of non-small-cell lung carcinoma with carbon-11-methionine: relationship between radioactivity uptake and flow-cytometric parameters. J Nucl Med. 1993;34:1886-1891.
21. 11C-methionine positron emission tomography and proliferating cell nuclear antigen staining. Neurosurg Rev. 1999;22:210-214.
22. 11C]methionine. Int J Radiat Oncol Biol Phys. 1994;30:1195-1199.
23. Rodriguez M, Rehn S, Ahlstrom H, Sundstrom C, Glimelius B. Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J Nucl Med. 1995;36:1790-1796.
24. 11C]-tyrosine PET. J Nucl Med. 1997;38:1369-1374.
25. Jager PL, Plaat BE, de Vries EG, et al. Imaging of soft-tissue tumors using L-3-[iodine-123]iodo-alpha-methyl-tyrosine single photon emission computed tomography: comparison with proliferative and mitotic activity, cellularity, and vascularity. Clin Cancer Res. 2000;6:2252-2259.
26. 3H]-Choline incorporation into MCF-7 cells: correlation with proliferation, choline kinase and phospholipase D assay. Anticancer Res. 2007;27:901-906.
27. Yoshimoto M, Waki A, Obata A, Furukawa T, Yonekura Y, Fujibayashi Y. Radiolabeled choline as a proliferation marker: comparison with radiolabeled acetate. Nucl Med Biol. 2004;31:859-865.
28. Yoshimoto M, Waki A, Yonekura Y, et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol. 2001;28:117-122.
29. 11C]choline does not correlate with cell proliferation in human prostate cancer. Eur J Nucl Med Mol Imaging. 2005;32:668-673.
30. Hauschka PV. Analysis of nucleotide pools in animal cells. Methods Cell Biol. 1974;7:361-462.
31. Sherley JL, Kelly TJ. Regulation of human thymidine kinase during the cell cycle. J Biol Chem. 1988;263:8350-8358.
32. Armstrong JS. Mitochondria: a target for cancer therapy. Br J Pharmacol. 2006;147:239-248.
33. Crawford EJ, Christman D, Atkins H, Friedkin M, Wolf AP. Scintigraphy with positron-emitting compounds. I. Carbon-11 labeled thymidine and thymidylate. Int J Nucl Med Biol. 1978;5:61-69.
34. 3H]thymidine uptake in rodent and canine neoplasms: concise communication. J Nucl Med. 1981;22:869-874.
35. Shields AF, Larson SM, Grunbaum Z, Graham MM. Short-term thymidine uptake in normal and neoplastic tissues: studies for PET. J Nucl Med. 1984;25:759-764.
36. Conti PS, Hilton J, Wong DF, et al. High performance liquid chromatography of carbon-11 labeled thymidine and its major catabolites for clinical PET studies. Nucl Med Biol. 1994;21:1045-1051.
37. Goethals P, van Eijkeren M, Lodewyck W, Dams R. Measurement of [methyl-carbon-11]thymidine and its metabolites in head and neck tumors. J Nucl Med. 1995;36:880-882.
38. Shields AF, Mankoff D, Graham MM, et al. Analysis of 2-carbon-11- thymidine blood metabolites in PET imaging. J Nucl Med. 1996;37:290-296.
39. Link JM, Grierson J, Krohn K. Alternatives in the synthesis of 2-[C-11]-thymidine. J Labelled Comp Radiopharm. 1995;35:610-612.
40. 11C]-thymidine for quantification of cellular proliferation with PET. Int J Rad Appl Instrum A. 1991;42:103-104.
41. Shields AF, Graham MM, Kozawa SM, et al. Contribution of labeled carbon dioxide to PET imaging of carbon-11-labeled compounds. J Nucl Med. 1992;33:581-584.
42. Vander Borght T, Pauwels S, Lambotte L, et al. Brain tumor imaging with PET and 2-[carbon-11]thymidine. J Nucl Med. 1994;35:974-982.
43. 11C]thymidine. Gastroenterology. 1991;101:794-799.
44. Mankoff DA, Shields AF, Graham MM, Link JM, Eary JF, Krohn KA. Kinetic analysis of 2-[carbon-11]thymidine PET imaging studies: compartmental model and mathematic analysis. J Nucl Med. 1998;39:1043-1055.
45. 11C]thymidine PET imaging studies of malignant brain tumors: preliminary patient results. Mol Imaging. 2002;1:145-150.
46. 11C]thymidine PET imaging studies of malignant brain tumors: compartmental model investigation and mathematical analysis. Mol Imaging. 2002;1:151-159.
47. Paterson AR, Kolassa N, Cass CE. Transport of nucleoside drugs in animal cells. Pharmacol Ther. 1981;12:515-536.
48. Cleaver JE. Thymidine metabolism and cell kinetics. Front Biol. 1967;6:43-100.
49. 2 and positron emission tomography. J Cereb Blood Flow Metab. 1984;4:458-465.
50. 2 and positron emission tomography. J Cereb Blood Flow Metab. 1984;4:8-16.
51. Shields AF, Coonrod DV, Quackenbush RC, Crowley JJ. Cellular sources of thymidine nucleotides: studies for PET. J Nucl Med. 1987;28:1435-1440.
52. Gunn RN, Yap JT, Wells P, et al. A general method to correct PET data for tissue metabolites using a dual-scan approach. J Nucl Med. 2000;41:706-711.
53. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334-1336.
54. Shields AF, Grierson JR, Kozawa SM, Zheng M. Development of labeled thymidine analogs for imaging tumor proliferation. Nucl Med Biol. 1996;23:17-22.
55. Toyohara J, Hayashi A, Sato M, et al. Development of radioiodinated nucleoside analogs for imaging tissue proliferation: comparisons of six 5-iodonucleosides. Nucl Med Biol. 2003;30:687-696.
56. 18F]FLT for imaging of cellular proliferation in vivo. Nucl Med Biol. 2000;27:143-156.
57. 18]fluoro-3′-deoxynucleosides. J Labelled Comp Radiopharm. 1997;40:60-62.
58. 18F]FLT). J Radioanal Nucl Chem. 2000;243:843-846.
59. Munch-Petersen B, Cloos L, Tyrsted G, Eriksson S. Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. J Biol Chem. 1991;266:9032-9038.
60. Muzi M, Vesselle H, Grierson JR, et al. Kinetic analysis of 3′-deoxy-3′-fluorothymidine PET studies: validation studies in patients with lung cancer. J Nucl Med. 2005;46:274-282.
61. Muzi M, Mankoff DA, Grierson JR, Wells JM, Vesselle H, Krohn KA. Kinetic modeling of 3′-deoxy-3′-fluorothymidine in somatic tumors: mathematic studies. J Nucl Med. 2005;46:371-380.
62. 18F]3′-deoxy-3′-fluorothymidine metabolism and retention. Eur J Nucl Med Mol Imaging. 2005;32:1269-1275.
63. 18FLT utilisation in colorectal cancer. Eur J Nucl Med Mol Imaging. 2004;31:169-178.
64. Shields AF, Grierson JR, Muzik O, et al. Kinetics of 3′-deoxy- 3′-[F-18]-fluorothymidine uptake and retention in dogs. Mol Imaging Biol. 2002;4:83-89.
65. 18F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res. 2002;62:3331-3334.
66. 18F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res. 2002;8:3315-3323.
67. 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2007;34:1610-1616.
68. 18F-fluorodeoxyglucose-positron emission tomography. Chest. 2006;129:393-401.
69. 18F-FDG. J Nucl Med. 2005;46:945-952.
70. 18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res. 2005;65:10104-10112.
71. 18F-FDG PET in esophageal cancer. J Nucl Med. 2005;46:400-404.
72. 11C]-FMAU): a potential nucleoside analog for in vivo study of cellular proliferation with PET. Nucl Med Biol. 1995;22:783-789.
73. 18F]labelled FAU, FMAU, FBAU, FIAU. Nucl Med Biol. 2003;30:215-224.
74. 14C]FMAU) in rat prostate tumor cells. Nucl Med Biol. 2000;27:361-368.
75. Bading JR, Shahinian AH, Vail A, et al. Pharmacokinetics of the thymidine analog 2′-fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (FMAU) in tumor-bearing rats. Nucl Med Biol. 2004;31:407-418.
76. 18F-FMAU and PET. J Nucl Med. 2005;46:292-296.
77. Wang H, Oliver P, Nan L, et al. Radiolabeled 2′-fluorodeoxyuracil- beta-D-arabinofuranoside (FAU) and 2′-fluoro-5-methyldeoxyuracil-beta-D- arabinofuranoside (FMAU) as tumor-imaging agents in mice. Cancer Chemother Pharmacol. 2002;49:419-424.
78. 18F]FMAU and positron emission tomography in patients with cancer. Eur J Nucl Med Mol Imaging. 2005;32:15-22.
79. 11C-FMAU): initial clinical studies [abstract]. J Nucl Med. 2002;43(suppl):26P.
80. 18F-3′-deoxy-3′-fluoro- l-thymidine (′FFLT): a pilot study. Eur J Surg Oncol. 2006;32:39-43.
81. Buck AK, Bommer M, Stilgenbauer S, et al. Molecular imaging of proliferation in malignant lymphoma. Cancer Res. 2006;66:11055-11061.
82. 18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer. Eur J Nucl Med Mol Imaging. 2003;30:988-994.
83. 18F-fluorothymidine in patients with gliomas. J Nucl Med. 2006;47:1612-1621.
84. 18F-FMAU) and PET. J Nucl Med. 2007;48:1436-1441.
85. Chou TC, Kong XB, Fanucchi MP, et al. Synthesis and biological effects of 2′-fluoro-5-ethyl-1-beta-D-arabinofuranosyluracil. Antimicrob Agents Chemother. 1987;31:1355-1358.
86. Wang J, Eriksson S. Phosphorylation of the anti-hepatitis B nucleoside analog 1-(2′-deoxy-2′-fluoro-1-beta-D-arabinofuranosyl)-5- iodouracil (FIAU) by human cytosolic and mitochondrial thymidine kinase and implications for cytotoxicity. Antimicrob Agents Chemother. 1996;40:1555-1557.
87. Eriksson S, Kierdaszuk B, Munch-Petersen B, Oberg B, Johansson NG. Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs. Biochem Biophys Res Commun. 1991;176:586-592.
88. Bergstrom M, Lu L, Fasth KJ, et al. In vitro and animal validation of bromine-76-bromodeoxyuridine as a proliferation marker. J Nucl Med. 1998;39:1273-1279.
89. 124I]iodo-2′- deoxyuridine for functional PET imaging of cell proliferation. Nucl Med Biol. 1998;25:359-365.
90. Tjuvajev JG, Macapinlac HA, Daghighian F, et al. Imaging of brain tumor proliferative activity with iodine-131-iododeoxyuridine. J Nucl Med. 1994;35:1407-1417.
91. 76Br]bromodeoxyuridine. Nucl Med Biol. 1999;26:795-802.
92. Tjuvajev J, Muraki A, Ginos J, et al. Iododeoxyuridine uptake and retention as a measure of tumor growth. J Nucl Med. 1993;34:1152-1162.
93. 76Br]bromo-2′-fluoro-2′-deoxyuridine as a ligand for tumour proliferation: validation in an animal tumour model. Eur J Nucl Med Mol Imaging. 2002;29:19-27.
94. 124I]iododeoxyuridine. Cancer Res. 2000;60:624-635.
95. 76Br-BrdU in DNA of brain tumors after a PET study does not support its use as a proliferation marker. Nucl Med Biol. 2001;28:59-65.
96. 76Br]bromofluorodeoxyuridine and its validation with regard to uptake, DNA incorporation, and excretion modulation in rats. J Nucl Med. 2000;41:1746-1752.
97. 18F-fluoro-1- β-D-arabinofuranosyl)-5-bromouracil: PET imaging studies in dogs. J Nucl Med. 2005;46:1916-1922.
98. 14C]thiothymidine for in vivo DNA synthesis imaging. J Nucl Med. 2006;47:1717-1722.
99. Nottebrock H, Then R. Thymidine concentrations in serum and urine of different animal species and man. Biochem Pharmacol. 1977;26:2175-2179.
100. 18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res. 2003;63:3791-3798.
101. 11C]FMAU) in monkeys [abstract]. J Nucl Med. 2000;41(suppl):234P.
102. 76Br-BFU as proliferation markers. J Nucl Med. 2002;43:1688-1698.
103. Calvar JA, Meli FJ, Romero C, et al. Characterization of brain tumors by MRS, DWI and Ki-67 labeling index. J Neurooncol. 2005;72:273-280.
104. McKnight TR, Lamborn KR, Love TD, et al. Correlation of magnetic resonance spectroscopic and growth characteristics within grades II and III gliomas. J Neurosurg. 2007;106:660-666.
105. Peet AC, Davies NP, Ridley L, et al. Magnetic resonance spectroscopy suggests key differences in the metastatic behaviour of medulloblastoma. Eur J Cancer. 2007;43:1037-1044.
106. Olsen G, Lyng H, Tufto I, Solberg K, Bjornaes I, Rofstad EK. Measurement of proliferation activity in human melanoma xenografts by magnetic resonance imaging. Magn Reson Imaging. 1999;17:393-402.
107. Ke S, Wen X, Gurfinkel M, et al. Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. Cancer Res. 2003;63:7870-7875.
108. Winnard P Jr, Raman V. Real time non-invasive imaging of receptor-ligand interactions in vivo. J Cell Biochem. 2003;90:454-463.
109. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 2003;17:545-580.
110. Diehn FE, Costouros NG, Miller MS, et al. Noninvasive fluorescent imaging reliably estimates biomass in vivo. Biotechniques. 2002;33:1250-1252, 1254-1255.
111. Papo N, Seger D, Makovitzki A, et al. Inhibition of tumor growth and elimination of multiple metastases in human prostate and breast xenografts by systemic inoculation of a host defense-like lytic peptide. Cancer Res. 2006;66:5371-5378.
112. 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med. 2004;45:695-700.
113. 18F-FDG PET. J Nucl Med. 2004;45:226-231.
114. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med. 2007;48:726-735.
115. Martiat P, Ferrant A, Labar D, et al. In vivo measurement of carbon-11 thymidine uptake in non-Hodgkin's lymphoma using positron emission tomography. J Nucl Med. 1988;29:1633-1637.
116. Shields AF, Mankoff DA, Link JM, et al. Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med. 1998;39:1757-1762.
117. 11C]thymidine in patients with squamous cell carcinoma of the head and neck. Acta Oncol. 1996;35:737-741.
118. Eary JF, Mankoff DA, Spence AM, et al. 2-[C-11]Thymidine imaging of malignant brain tumors. Cancer Res. 1999;59:615-621.
119. Buck AK, Hetzel M, Schirrmeister H, et al. Clinical relevance of imaging proliferative activity in lung nodules. Eur J Nucl Med Mol Imaging. 2005;32:525-533.
120. 18F]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions? J Thorac Cardiovasc Surg. 2004;127:1093-1099.
121. 18F-3′- fluoro-3′-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer? J Nucl Med. 2004;45:1677-1682.
122. Herrmann K, Ott K, Buck A, et al. Detection of locally advanced gastric cancer with fluoro-18-thymidine and fluoro-18-fluorodeoxyglucose positron emission tomography [abstract]. J Nucl Med. 2007;48(suppl):27P.
123. 18F]3′-Deoxy-3′- fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imaging. 2005;32:653-659.
124. 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med. 2005;46:1948-1958.
125. 18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging. 2002;29:1462-1469.
126. 11C]Thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337. J Natl Cancer Inst. 2003;95:675-682.
127. 18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice. J Nucl Med. 2004;45:1754-1758.
128. 18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res. 2005;65:4202-4210.
129. 18F]fluorothymidine positron emission tomography. Cancer Res. 2006;66:7621-7629.
130. 18F-fluorothymidine PET. J Nucl Med. 2005;46:114-120.
131. Pio BS, Park CK, Pietras R, et al. Usefulness of 3′-[F-18]fluoro- 3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol. 2006;8:36-42.
132. 18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res. 2007;13:3552-3558.
133. 18F-fluoro-deoxythymidine [abstract]. J Nucl Med. 2007;48(suppl):350P.
134. 18F-FLT PET is a powerful predictor for overall survival in patients with malignant gliomas treated with bevicuzimab and irinotecan [abstract]. J Nucl Med. 2007;48(suppl):10P.
135. Shields AF, Lawhorn-Crews JM, Briston DA, Douglas KA, Mangner TJ, Muzik O. The reproducibility of FLT PET in patients with untreated non-small cell lung cancer [abstract]. J Nucl Med. 2005;46(suppl):426P.
136. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007;48:932-945.